Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs

Immunotherapy

Volumn 5, Issue 12, 2013, Pages 1347-1355

  Slovin, Susan F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

antibody drug conjugates; monoclonal antibodies; prostate cancer; PSA; PSMA; vaccines

Indexed keywords

ANTIBODY CONJUGATE; ANTIMITOTIC AGENT; ASG 5ME; CAPROMAB PENDETIDE IN 111; CITRULLINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DSTP3086S; IBRITUMOMAB TIUXETAN; IPILIMUMAB; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591 LUTETIUM 177; NIVOLUMAB; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; RADIOPHARMACEUTICAL AGENT; SIPULEUCEL T; SIX TRANSMEMBRANE EPITHELIAL ANTIGENS OF THE PROSTATE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VALINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CONSTIPATION; CYTOTOXICITY; DECREASED APPETITE; DIARRHEA; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ELECTROSPRAY MASS SPECTROMETRY; FATIGUE; HUMAN; IMMUNOGENICITY; LIVER FUNCTION; LOADING DRUG DOSE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; MELANOMA; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR REGRESSION; ULTRAVIOLET SPECTROSCOPY; VOMITING;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84889593208     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.140     Document Type: Review

References (52)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Eng. J. Med. 363, 711-723 (2010)
2. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010)
3. Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol. 24(7), 1813-2181 (2013)
4. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11, 728-734 (2005) (Pubitemid 40116901)
5. Hartsell WF, Scott CB, Bruner DW et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J. Natl Cancer Inst. 97, 798-804 (2005) (Pubitemid 40909122)
6. Bristol-Myers Squibb. Bristol-Myers Squibb reports results for Phase 3 trial of Yervoy® (ipilimumab) in previously-treated castration-resistant prostate cancer. Copyright Business Wire, 12 September (2013)
7. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012)
8. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012)
9. Wolchok J, KLuger HM, Callahan MK et al. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL) Proc. Am. Soc. Clin. Oncol. 31, Abstract 9012 (2013)
10. Teicher B, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 17, 6389-6397 (2011)
11. Maloney D, Morschhauser F, Linden O, Hagenbeek A, Gisselbrecht C. Diversity in antibody-based approaches to non-Hodgkin lymphoma. Leuk. Lymphoma. 51(Suppl. 1), 20-27 (2010)
12. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell Biochem. 91(3), 528-539 (2004)
13. Reiter RE, Gu Z, Watabe T et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl Acad. Sci. USA 95, 1735-1740 (1998) (Pubitemid 28103463)
14. Danila DC, Szmulewitz RZ, Higano CS et al. A Phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) J. Clin. Oncol. 31(Suppl.), Abstract 5020 (2013)
15. Slovin SF, Govindaswami R, Musselli C et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with a-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J. Clin. Oncol. 21, 4292-4298 (2003) (Pubitemid 46621804)
16. Slovin SF. Emerging role of immunotherapy in the management of prostate cancer. Oncology 21, 326-333 (2007) (Pubitemid 46481983)
17. Trail PA. Antibody drug conjugates as cancer therapeutics. Antibodies 2, 113-129. (2013)
18. Gudas JM, An Z, Morrison RK et al. ASG-5ME is a novel antibody drug conjugate (ADC) for treating prostate cancers. Cancer Res. 70(8 Suppl. 1), Abstract 4393 (2010)
19. Bai R, Friedman SJ, Pettit GR, Hamel E. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem. Pharmacol. 43, 2637-2645 (1992)
20. Xu K, Liu L, Dere R et al. Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum. Bioanalysis 5, 1057-1071 (2013)
21. Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 37, 261-269 (1998) (Pubitemid 28524659)
22. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 23, 4591-4601 (2005) (Pubitemid 46224061)
23. Vallabhajosula S, Goldsmith SJ, Hamacher KA et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y-and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J. Nucl. Med. 46, 850-858 (2005)
24. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky M, Nanus DM, Bander NH. Phase I clinical trials with 177Lu-DOTA-J591 monoclonal antibodies in patients with prostate cancer: single high-dose vs. fractionated multi-dose treatment. J. Nucl. Med. 45, P389 (2004)
25. Gudas JM, An Z, Morrison RK et al. ASG-5ME is a novel antibody drug conjugate (ADC) for treating prostate cancers. Programs and Abstracts of the 101st Annual ACR. Washington, DC, USA, April 17-21 2010 (Abstract 4393)
26. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol. Cancer Ther. 9, 2689-2699 (2010)
27. Galsky MD, Eisenberger M, Moore-Cooper S et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol. 26, 2147-2154 (2008)
28. Hamblett KJ, Senter PD, Chace DF et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-7070 (2004) (Pubitemid 39383058)
29. Issell BF, Crooke ST. Maytansine. Cancer Treat. Rev. 5, 199-207 (1978)
30. Cabanillas F, Bodey GP, Burgess MA, Freireich EJ. Results of a Phase II study of maytansine in patients with breast carcinoma and melanoma. (1979) Cancer Treat. Rep. 63, 507-509 (1979) (Pubitemid 9192260)
31. Challita-Eid PM, Morrison K, Etessami S et al. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res. 67, 5798-5805 (2007) (Pubitemid 46985013)
32. Danila DC, Szmulewitz RZ, Higano CS et al. A Phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) Proc. Am. Soc. Clin. Oncol. 31(Suppl. 15), Abstract 5020 (2013)
33. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin. Cancer Res. 17, 3903-3912 (2011)
34. Schülke N, Varlamova OA, Donovan GP et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc. Natl Acad. Sci. USA 100, 12590-12595 (2003) (Pubitemid 37339943)
35. Slovin SF. PSMA vaccines: naked DNA and protein approaches. Clin. Prostate Cancer 4, 1-6 (2005)
36. Slovin S, Gregor P, Wolchok J et al. A xenogeneic PSMA DNA vaccine for patients (pts) with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC) -a Phase I trial of proof of principle. Proc. Am. Assoc. Clin. Oncol. 25(Suppl. 18), Abstract 3073 (2007)
37. Gardner JP, Slovin SF, Morrissey DM et al. Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine: preliminary findings of a Phase I safety/immunogenicity trial. Proc. Am. Assoc. Clin. Oncol. 22(Suppl. 14), Abstract 2584 (2004)
38. Slovin SF, Kehoe M, Durso R et al. Phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (psma) in subjects with prostate cancer. Vaccine 31, 943-949 (2013)
39. Akhtar NH, Osborne J, Nanus DM et al. Non-invasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: a promising biomarker for PSMA-based radioimmunotherapy. Presented at: The 104th Annual AACR Meeting 2013. Washington, DC, USA, April 6-10 2013 (Poster 4696)
40. Olafson T, Ho DT, Lipman AA et al. Highly specific small animal PET imaging of prostate specific membrane antigen (PSMA) xenografts by an engineered humanized antibody fragment (minibody) Presented at: American Association of Pharmaceutical Scientists. 8 September 2010.
41. Viola-Villegas N, Evans H, Bartlett D, Wu A, Lewis J. Preclinical development of Zr-89 labeled anti-PSMA minibody and cys-diabody. J. Nucl. Med. 53(Suppl. 1), Abstract 347 (2012)
42. Ma D, Parsons T, Olson WC. Single-dose activity of PSMA ADC against prostate cancer xenograft and explant tumors. Proc. Am. Assoc. Clin. Oncol. 28(Suppl.), Abstract e13534 (2010)
43. Rotshteyn Y, Mercier F, Bruno R, Stambler N, Israel RJ, Wong V. Correlation of PSMA ADC exposure with reduction in tumor growth rate determined using serial PSA measurements from a Phase I clinical trial. J. Clin. Oncol. 31(Suppl.), Abstract e16047 (2013)
44. Petrylak DP, Kantoff PW, Mega AE et al. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): a Phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. Proc. Am. Soc. Clin. Oncol. 31(Suppl.), Abstract 5018 (2013)
45. Saeki N, Gu J, Yoshida T, Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin. Cancer Res. 16, 3533-3538 (2010)
46. Reiter RE, Gu Z, Watabe T et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl Acad. Sci. USA 95, 1735-1740 (1998) (Pubitemid 28103463)
47. Gu Z, Thomas G, Yamashiro J et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19, 1288-1296 (2000) (Pubitemid 30160621)
48. Saffran DC, Raitano AB, Hubert RS et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Natl Acad. Sci. USA 98, 2658-2663 (2001) (Pubitemid 32209538)
49. Antonarakis ES, Carducci MA, Eisenberger MA et al. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration resistant prostate cancer: a PCCYC trial. Chemother. Pharmacol. 69, 763-771 (2012)
50. Morris MJ, Eisenberger MA, Pili R et al. A Phase I/II study of AGS-PSCA for castration-resistant prostate cancer. Ann. Oncol. 23, 2714-2719 (2012)
51. Ribas A, Chmielowski B, Glapsy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin. Cancer Res. 15, 7116-7118 (2009)
52. Scher HI, Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55, 323-327 (2000) (Pubitemid 30110575)